(Q37832934)

24 August 2017

1 reference

title

A review of cost-effectiveness studies in ovarian cancer (English)

1 reference

cost-effectiveness analysis

24 August 2017

1 reference

1 reference

2

Laura J Havrilesky

1 reference

24 August 2017

Gregory P Sfakianos

1

1 reference

24 August 2017

publication date

1 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

18

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

59-64

1 reference

24 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Cost of care for elderly cancer patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Treatment preferences in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Analytic tools for public health decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

The CA 125 tumour-associated antigen: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Screening for ovarian cancer: a pilot randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Quantifying the potential benefit of CA 125 screening for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Results from four rounds of ovarian cancer screening in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

The performance of screening tests for ovarian cancer: results of a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800109

10.1177/107327481101800109

21 January 2018

Identifiers

DOI

0 references

1 reference